Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of patients receiving anakinra for gouty arthritis.

From: Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

Baseline characteristics Clinical characteristics of gouty patients
Number of patients 40
Number of men (%) 32 (80%)
Comorbid conditions (number; %) HT (27; 68%), CKD 3-5 (22; 55%), CAD (17; 43%), AI (13; 33%), DM (9; 23%), GU (6; 15%), transplant (2 (kidney, heart); 5%), asthma (1; 3%),
Associated therapies (number; %) LDA (8; 20%), oral anticoagulant (3; 8%),
Age, year, mean ± SD 60.0 ± 13.9
Disease duration, year, mean ± SD 8.7 ± 8.7
Flare duration, number patients (days, mean ± SD)  
   Acute (<6 weeks) 34 (9.4 ± 8.1)
   Subacute (6 to12 weeks) 2 (60.0 ± 1.4)
   Chronic (>12 weeks) 4 (130 ± 45.8)
Localization of arthritis, (number; %) Knees (30; 75%), wrists (22; 55%), ankles (24; 60%), MTP1s (20; 50%), MCPs (12; 30%), elbows (12; 30%), tarsae (6; 15%), shoulders (2; 5%)
Reason for anakinra use  
   Non-response to conventional therapies, (number; %) Colchicine (24; 60%), NSAIDs (11; 27.5%), steroids (7; 17.5%)
   Adverse events or contraindication to conventional therapies, (number; %) Colchicine (16; 40%), NSAIDs (29; 72.5%), steroids (9; 22.5%)
  1. AI, alcohol intake; CAD, coronary heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; GU, gastric ulcer; HT, hypertension, LDA, low-dose aspirin; MCPs, metacarpophalangeal joints; MTPs, metatarsophalangeal joints; NSAIDs, non-steroidal anti-inflammatory drugs.